A 5-year-old boy presented with a six month history of neuroblastoma, primary to the adrenal gland and metastatic to the distal femora with a positive bone marrow aspirate. He originally received multi-agent chemotherapy and underwent resection of the primary adrenal mass after achieving bone marrow remission.
At outside institutions, eventual F18-FDG PET scan (not shown) and bone marrow aspiration demonstrated no evidence of active disease.
Discussion
Hematopoietic growth factors are marrow regulators which support proliferation and differentiation of blood cells of different lineages [10] [11] . Recombinant granulocyte colony-stimulating factor (GCSF) (Neupogen, Amgen) is frequently used as an adjunct to chemotherapy, especially when administered in high doses, in order to stimulate the marrow to produce more white blood cells, therefore counteracting the myelosuppressive effects [1] [2] [3] [4] .
Magnetic resonance (MR) imaging has been shown to demonstrate bone marrow signal changes related to the reconversion from fatty to hematopoietic marrow induced by GCSF. In children, marrow reconversion is usually limited to the extremities due to the normal progression of conversion of red to fatty marrow starting in the epiphyses and extending into the metaphyses and then diaphyses over approximately two decades. GCSF-induced marrow signal changes are nonspecific, characterized by decreased signal on T1W and increased signal on fluid-sensitive sequences in regions with previously demonstrated normal yellow marrow [4] [5] [6] [7] [8] [9] . MR is typically used to follow the response to chemotherapy for many musculoskeletal tumors, and such bone marrow signal changes may be difficult to differentiate from recurrent or metastatic disease [5, 9, [12] [13] . Nonetheless, certain observations may aid in this differentiation.
Alterations in marrow signal on MR imaging related to GCSF therapy have been shown to coincide with elevations in the peripheral white blood cell count [1] [2] [3] . This was demonstrated in our case, with the initial MR marrow signal changes appearing with a substantial increased in the peripheral leukocyte count. Subsequent imaging revealed decreased marrow signal abnormalities coinciding with normalization of the leukocyte count. There is paucity of information in the literature regarding the persistence of abnormal marrow signal related to GCSF therapy.
Noting the time interval between initiation of therapy and onset of MR marrow signal changes may lend support for GCSF effects. Fletcher et al demonstrated a median of 16 days between initiation of GCSF therapy and development of MRI marrow signal alterations [1] . In our case, such MRI findings were observed three weeks after the initiation of therapy.
Bone marrow reconversion often exhibits the typical pattern of diffusely increased skeletal radiotracer uptake on Tc99m-MAA and FDG-PET scanning [3] . Furthermore, lower standard uptake values (SUV) favor red marrow reconversion over tumor. Seven weeks after initiation of
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GCSF therapy, our patient underwent I131-mIBG scan which showed no evidence of metastatic neuroblastoma. The subsequent F18-FDG PET scan also showed no active metastases.
Although disseminated osseous metastatic disease may demonstrate diffuse marrow signal changes on MRI and increased radiotracer uptake on scintigraphic studies, clinical signs of such progressive disease would also be expected. Clinical observations coincided with imaging findings, as our patient continued to show no signs of disseminated disease Histologic confirmation is usually not necessary if typical imaging and clinical findings argue against the presence of metastatic disease. Despite strong supporting evidence, our patient eventually underwent bone marrow aspiration, which was negative and affirmed our conclusion.
